Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 1/20 | 0.33 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19590180 | 0.81 | PYGM (0.35) | — | |
| SCHEMBL6674416 | 0.72 | CDA (0.47) | — | |
| SCHEMBL20833069 | 0.72 | CDA (0.47) | — | |
| SCHEMBL16855719 | 0.72 | P2RY2 (0.58) | P2RY2P2RY4P2RY6 | |
| SCHEMBL20356797 | 0.67 | CDA (0.50) | — | |
| SCHEMBL19866473 | 0.63 | — | — | |
| SCHEMBL20257679 | 0.61 | SLC28A1 (0.68) | P2RY2P2RY4P2RY6 | |
| SCHEMBL16855712 | 0.61 | SLC28A1 (0.68) | P2RY2P2RY4P2RY6 | |
| SCHEMBL17929404 | 0.61 | CDA (0.34) | — | |
| SCHEMBL23750588 | 0.61 | ALDH1A1 (0.42) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10683321-B2 | 4′-or nucleosides for the treatment of HCV | IDENIX PHARMACEUTICALS LLC (US) | 2020-06-16 | — | — | US | disclosed |
| US-20180162898-A1 | 4'-OR NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS LLC (US) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10683321-B2 | 4′-or nucleosides for the treatment of HCV | NSUN2, NSUN3, ZC3HAV1 | P2RY2 1203/4885P2RY4 337/4885ALDH1A1 516/4885 |
| US-20180162898-A1 | 4'-OR NUCLEOSIDES FOR THE TREATMENT OF HCV | NSUN2, NSUN3, ZC3HAV1 | P2RY2 1203/4885P2RY4 318/4885ALDH1A1 483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.